Hematology

Switching to Rituximab Biosimilars Is Safe, Effective for Patients With Oncohematological Diseases

December 5th 2024

By Cameron Santoro

Patients with oncohematological diseases switching to rituximab biosimilars experienced similar safety and efficacy, highlighting biosimilars' potential for cost-effective treatment across various medical conditions.

Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline

August 3rd 2024

By Skylar Jeremias

Article

Products in line to face biosimilar competition are projected to increase their list prices in advance, according to Vizient’s Pharmacy Market Outlook Report for Summer 2024.

FDA Approves Epysqli as Second Soliris Biosimilar

July 22nd 2024

By Skylar Jeremias

Article

The FDA approves Samsung Bioepis’ Epysqli (eculizumab-aagh), marking the second US approval for a biosimilar referencing Soliris (eculizumab).

EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions

June 27th 2024

By Skylar Jeremias

Article

Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.

EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris

June 15th 2024

By Skylar Jeremias

Article

A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).

FDA Approves First Eculizumab Biosimilar

May 29th 2024

By Skylar Jeremias

Article

The FDA approved Bkemv (eculizumab-aeeb) as the first biosimilar to Soliris (eculizumab) for 2 rare diseases. It was also approved with interchangeability.

Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs

March 29th 2024

By Skylar Jeremias

Article

Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.

Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials

February 10th 2024

By Deana Ferreri, PhD

Article

The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.

Rituximab Biosimilars Effective in Treating Immune Thrombocytopenia

January 15th 2024

By Cameron Santoro

Article

A French study found that rituximab biosimilars, Rixathon and Truxima, were as effective and safe as the reference drug (Rituxan) in treating immune thrombocytopenia.

Enoxaparin Biosimilar Shows Similar Efficacy to Originator in Preventing Postoperative Subclinical Thrombosis

December 16th 2023

By Deana Ferreri, PhD

Article

The biosimilar Enoxa (enoxaparin), marketed in Tunisia, demonstrated equivalence in preventing subclinical postoperative thrombotic events in patients with digestive cancers to Sanofi’s Lovenox, in a randomized controlled trial.